Pre-Market 25 Mar 2026: AIDX.TO Healwell AI TSX C$0.84, model risks C$0.72

AIDX.TO stock opens pre-market on 25 Mar 2026 at C$0.84, down 1.18% from the prior close. Trading volume is light at 154,460 shares versus a 50-day average of 552,374. The healthcare tech company Healwell AI Inc. (AIDX.TO, TSX) shows a mixed profile: negative earnings per share -0.23 and a trailing PE of -3.65, but a 50-day average price near C$0.80. We use these facts to frame short-term risk and a data-driven outlook for AI-focused healthcare investors.

AIDX.TO stock: current price action and market context

Healwell AI Inc. (AIDX.TO) trades at C$0.84 pre-market on the TSX in Canada. Volume today is 154,460 versus an average of 552,374, giving a relative volume of 0.28. The stock’s 52-week range is C$0.58 to C$1.77, and the 50-day average price is C$0.80, signaling near-term consolidation. Sector weakness in Healthcare helps explain the muted flow, while the company’s AI focus keeps it on growth screens.

AIDX.TO stock: financials and valuation metrics

Healwell AI reports EPS -0.23 and a trailing PE of -3.65, reflecting continued losses. Key ratios include Price/Book 1.97, Debt/Equity 0.69, and Current Ratio 0.91, showing modest leverage and tight short-term liquidity. Price to sales is about 1.99, and operating cash flow per share is -0.07, indicating negative operating cash generation. These figures frame a valuation case that relies on improved margins and recurring revenue from AI products.

AIDX.TO stock: technical setup and trading signals

Technicals show neutral momentum with RSI 50.85 and MACD slightly negative. ADX is 32.89, which signals a strong trend in place. Bollinger Bands sit at Upper C$1.03, Middle C$0.85, and Lower C$0.66, placing price near the band center. Short-term support is near C$0.82 and resistance near C$0.95. Traders should note low relative volume and on-balance-volume negative bias when sizing positions.

AIDX.TO stock: Meyka AI grade and model forecast

Meyka AI rates AIDX.TO with a score of 62 out of 100 (Grade B, SUGGESTION: HOLD). This grade factors S&P 500 comparison, sector and industry metrics, financial growth, key ratios, forecasts, and analyst signals. Meyka AI’s forecast model projects monthly C$0.65, quarterly C$0.72, and yearly C$0.40. Versus the current price C$0.84, the quarterly projection implies -14.29% downside, and the yearly projection implies -52.52% downside. Forecasts are model-based projections and not guarantees.

AIDX.TO stock: risks and opportunities for AI investors

Opportunity: Healwell AI’s AI decision-support products and the strategic alliance with WELL Health can drive recurring revenue if adoption scales. Risk: negative operating cash flow per share -0.07, long days sales outstanding 122 days, and a current ratio below 1.0 increase liquidity risk. A rebound would require visible contract wins or margin improvement in the next two quarters. Keep earnings on the radar: the next report is set for 13 May 2026.

AIDX.TO stock: analyst view, targets, and trading strategy

Consensus sell-side coverage is limited and external ratings show recent weak scores. Realistic short-term price targets: a conservative rebound to C$0.95 and a medium-term target to C$1.25 if revenue growth and cash flow improve. A bear scenario aligns with Meyka’s yearly projection near C$0.40. Position sizing for AI stock exposure should limit position weight and use stop loss bands near C$0.70 on tight risk management.

Final Thoughts

Key takeaways: AIDX.TO stock trades pre-market at C$0.84 with light volume and mixed signals across fundamentals and technicals. The company posts EPS -0.23 and a negative operating cash flow per share -0.07, which heightens near-term liquidity risk. Meyka AI rates AIDX.TO 62/100 (Grade B, HOLD) and its forecast model projects quarterly C$0.72 and yearly C$0.40, implying downside of -14.29% and -52.52% versus today. For AI stock investors, monitor revenue cadence, WELL Health partnership updates, and the 13 May 2026 earnings date. Short-term traders may look for a move above C$0.95 as a confirmation, while longer-term holders need margin improvement and cash flow stabilization. Meyka AI provides this as an AI-powered market analysis platform view, not investment advice. For live news and transcript context see Seeking Alpha and Healwell AI’s site Healwell AI.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.